Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 10/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408086 | 0.94 | HCRTR2 (0.51) | HCRTR2HCRTR1HTR6MTNR1AMTNR1B | |
| SCHEMBL2407485 | 0.91 | HCRTR2 (0.39) | HCRTR2HCRTR1CDK4CCND1HTR2A | |
| SCHEMBL2410403 | 0.89 | HTR1A (0.40) | HCRTR2HCRTR1CDK4CCND1 | |
| SCHEMBL2404821 | 0.89 | HCRTR2 (0.39) | HCRTR2HCRTR1 | |
| SCHEMBL2409735 | 0.89 | HCRTR2 (0.46) | HCRTR2HCRTR1HTR6MTNR1AMTNR1B | |
| SCHEMBL2405245 | 0.88 | CDK4 (0.42) | HCRTR2HCRTR1KMT2AMEN1CDK4 | |
| SCHEMBL2405458 | 0.87 | HCRTR1 (0.44) | HCRTR2HCRTR1 | |
| SCHEMBL2410043 | 0.86 | HCRTR2 (0.40) | HCRTR2HCRTR1HTR6MTNR1AMTNR1B | |
| SCHEMBL2404985 | 0.85 | HTR6 (0.43) | HCRTR2HTR6MTNR1AMTNR1BKMT2A | |
| SCHEMBL2410706 | 0.85 | HCRTR1 (0.46) | HCRTR2HCRTR1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | HCRTR2 1/4885HCRTR1 2/4885HTR6 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.